Administration of cyclosporine (CS
properties, has significantly improved survival in organ and bone marrow transplant recipients.
Despite this success, the value of the drug has been lessened by its clinically significant side effects. Prominent among these effects, which have been extensively stLldied in both humans and in experimental animals, are nephrotox[c~ty aid hypertension (1) (2) (3) (4) (5) .
Other serious problems include: hepatic dysfunction, tremor, convulsions, hirsutism and gingival hyperplasia (see I, 6-8 for review).
Changes in renal function appear rapidly following C$ administration and persist during chronic treatment.
Acute intravenous administration of CS (20mg/kg) to rats caused a 26% reduction in glomerular filtration rate and a transient increase in blood pressure (9) as well as a 48% decrease in renal blood flow and an 80% increase in renal vascular resistance (8) . An intravenous dose of 10mg/kg caused a 69% iacrease in efferent renal nerve activity (I0), suggesting that at least part of the effect of CS on renal function m~y be indirect.
Chronic CS treatment is associated with elevations of serum urea and creatinine, depressed inulin clearance (1, 2, (5) (6) (7) (8) 11) , and a red, lction in renal blood flow (12).
Alth~igh ~tr,Lctural changes have been repo~ted
[,~ the proximal tub,le of the rat (I]) and human (13), CS nephrotoxicity appears to be readily ceversible upon withdrawal of the drng.
These observations have lead several authors to speculate that the nephrotoxic effect of CS is mediated primarily through a hemodynamic actiou of the drug (6, 8, 14) .
The et~ology of the elevation of arterial blood p re~;1~:e is unknown and this change appears to develop independently of known cardiovascular risk factors (3).
It has been postulated that generalized vascular damage is at least partially responsible.
Pathologic changes have been observed in both arteriolar s,~oth muscle (5) and endothelia~ cel1~; (LS).
Other authors have suggested that the renin-~Igiotensin-aldosterone system is involved. This specnlat~o,~ is based on the observation of elevations in plasma renin activity (PRA) in CS-treated rats (5, 7) These patie~its develop hypertension in assoc~at~o,~ with this elevated vascular resistance.
The observation of concurrent alterations in renal function, renal blond flow and systemic vascular resistance led us to hypothesize that cyclosporine alters vascular function, either directly or through an effecl o~i adrenergic neurotransmission.
This hypothesis was tested by measuring the effect of CS on force develo~nent in isolated segments of vascular s,~o th muscle responding to physiologic stimuli.
Methods
Adult male Sprague-Dawley rats (300-350g) were anesthetized with sodium pentobarbital (50mg/kg) and tail arteries and portal veins were removed. The vessels were cleaned of adherent fat and connective tissue under a dissecting microscope. Tail arteries were cut helically i,~to strips (0.7 x 10mm), portal veins were slit longitudinally.
The tissues were mounted vertically in an organ chamber containing physiologic salt solution (PSS) for measurement of isometric force generation as described elsewhere (19).
Transmural nerve stimulatiou (TNS) was delivered via parallel platinn1~ wire electrodes.
A stimulator (Grass ~del $4) delivered 9 volt square wave pulses of i mseC duration ove~-a range of frequencies.
Ascocbic acid (10-4M) was added to the buffer during stlmulation periods in order to prevent cellular da~ge due to free radical formation at the electrodes. Cyclospori~e was delivered from the IV preparation (Sandimmun) and control experiments were performed u~i,~g the vehicle compound, cre~)phor EL plus ~ t hanol (provided by Sandoz Pharu~ ce tt~ cals ). Other drugs L1sed were norepinephrine bitartrate (Lev~phed, Sterling Drug Inc., New Yo~-k, H~') v~id phentolamine mesylate (Regitine, CIBA Pharmaceutical Co., Summit, NJ).
Statistical analysis was performed using either a Student's t-test with the Bonferroni correction or a one-way analysis of variance with a least significant difference test.
A p-value of less than 0.05 was considered to be statistically significant.
Results
Prolouged incubation (2 hours) of unstimulated tail artery strips in CS (8.3 x 10-6M) did not elicit a contractile response.
However, the presence of CS did alter the response to known vasoconstrictor stimuli whereas the The tracing depicts a typical experiment.
Asterisk indicates a significant difference at p 0.05, (N=8).
vehicle soluti~a had no such properties. Figure I ~ho~ the response of the isolated tail artecy to adr'energ~c nerve stimulation as the frequency of TNS is varied fco,i 9.I to 16Hz.
These neural respo:tse~ c4,i be blocked completely by tetrodotoxin or by phentolamine.
Following a I0 rain incubatio, i in CS, a significa:It increase is observed in the responsiveness to TNS. Appropriate time control studies were aim) performed and no significant changeq ~ere observed i,~ the frequency response curve.
Since CS augmented responses to e,~dogenously released norepinephrirle~ the effect of CS on responses to exogenously applied norepinephrine (fig, lre  2) was evaluated.
Tail arteries were n~ade to contract repeatedly (3 mi~i contractions) in response to a low concentration of norepinephrine (5.9 x 10-9M, an approx. ED I0 do s e ) un ti 1 a ~a tab le co n tr ol r es po ns e was established.
Following a I0 min incubatio1~ in CS a significant potentiation of the contractile response to an identical concentration of norepiJiephr[ne was observed.
This effect was reversed following washout of CS.
600,
I.-.. F~gu~e 3 ill~mt~ates contractile respo,~e~ of tail artery strips which were induced by changing the potassium concentration of the PgS (10-50raM). The presence of CS (8.3 x i0-6M) augmented the contractile response observed at a given concentration of potassium.
These experiments were performed in the presence of phentolamine in order to prevent an effect of norepinephrine released ~=,'om depolarized adrenergic nerve endings (20).
The portal we[~ of the rat undergoes spontaneo~l~ phasic contractile events under isolated c~ di tions. Figure 4 demonstrates that increasing con ce~1 tra t ions of ~ (8.3 x 10 -7 -8.3 x i0-5M, 10rain inc~Iba tions) increased the frequency of these myogenic events.
,~ L~ c,,ss ion
These studies s,lpport olr 9reliminary observations (21) and ~uggest that CS can exert direct effects upon vascular s u~ootl~ ~scle.
This action leads to an au green tat io,~ ~ co,~ tractile responsiveness ~1[ch ,nay c~l tr ibu te directly to c q-induced hypertension or may help to [~itiate the changes in renal blood flow and subsequent ne phro to xi city associated with CS administration (6, 8, 13 ).
The ability of CS to potentiate responses to stimulation of the vascular adrenergic nerve endings could be explained by either an action of CS to augment adrenergic neurotransmission or a direct effect of CS on smooth muscle cells.
Our experiments which demonstrate a CS-induced increase in responses to exogenous nor epinephrine support the latter conclusion. However, CS is known to aLlgment renal ~ympathetic nerve activity (i0) and to increase heart rate (5), therefore .t c~,nb[nat~ol of effects on both necves and smooth muscle re,~ins an attractive hypothesis.
The effecI: ~f C~q o,~ responses of the tail artery to depolarizing concentrations of potassium suggests that CS ,~ay alter resting membrane potential, bringing the tissue closer to threshold for contraction. This conclusion is supported by the ability of CS to increase the frequency of spontaneous contractions in the portal vein.
These spontaneou~ events have been sho~n to be associated with firing of a calcium-driven action potential in the smooth muscle cells.
The frequency of their firing is increased Result~ are e~pressed as the number of co,ltractim~s occurring within a 5 rain period.
Upper panel shows the response of one vein.
Asterisks indicate a significant effect at p 0.05, (N=4).
following depolar [za t~ on (22). However, unlike po tass i,nn-in du ced depolarizat;o~, cyclosporine did not increase the a~J~p]it,lde of portal vein contractions.
T1,e reason for this difference is tlnele~r. ~ ;YDiILty of cyclosporine to ca~lqe partial depolarization would a1~;o be co,~sistent with the observed alteration in response to en do ge,~ous m~d exogenous norepinephrine.
A decrease in membrane potential has been ~howa to [~icrease both release of no~'ep[nephrine from adrenergic nerve endi~igs (20) and smooth muscle responses to applied norepinephrine (23).
Whatever the action nE cye]o~porine, it appears to be act[qg ;~t the level of the ola~ma membrane.
Responses of the blood vessel in calcium-free solution depend upon the release of intracellular calcium stores (24).
In our e~perLue~:ts, cyclosp~,-i~e had no effect on the magnitud,~ of the~e ~:asic contractions. C5 iah[B:ts phospholipase A 2 activity i,~ %~th rat ~td human ~ite blood cell~ (25, 26) and can alter prostanoid release from human peripheral blood mononuclear cells (27) .
CS had no effect on cytosolic free calcium concentration in unsti,uulated rat hepatocytes or on resting calcium uptake into mouse lymphocytes. However, the drug was able to aug, nent the receptor-mediated rise [n intracellular calcium ~nen the hepatocytes ~ece stimulated with vasopre:~si:~ aad to L~crease the uptake of calcium ;nto ,a: to gen-s timula ted I ~nphocyte~ (28, 29) . T]: ese observations pa_~allel o,~,-,'eq~Its ~ere despite an appacent lack of vasoconstrictor properties, C3 is able to increase vascular react[,r~ty to known constrictor stimuli.
The clinical significance of these expeci;aeats is unclear.
The present :na~ ,iv using I0 mln exposures to cyclospori:~e at a ~t~idies were performed pr" -:' " " co.:ce!~tratioa of 8.3 x I0 '~ (10 5 g/ml).
Clinical ~esults (30,31) have suggested that optiu:l t¢ough plasma levels of cyclospo~lne i~ ~a,~ are somewhat lowe~ tha~ this, in the range of 2 x 10 -7 g/ml (lO-6g/ml of whole blood).
However, the rat has been shown to be relatively resistant to the immunosuppre~sive effects of cyclosporine c~npared to man (II). In addition, while these in vitro studies involve very short exposures to this co~pou~:d, c]inical treatment with cyclospor[ne may continue for months o¢ years.
Regardless, these expeci, aeats demonstrate a direct vasc~lac effect ~ich may be associated with the hypertensive a~d ~ephrotoxic side effects of cyc los por ine. L7 1973-1975 (1985 
